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0.21-0.79; p=0.0075). After multivariable analysis, the management during the
period 2 remained a strong protective factor (adjusted hazard ratio=0.26; 95%
confidence interval, 0.09-0.76; p=0.014). During period 2, we observed a sig-
nificant better compliance in antimicrobial therapy and fewer cases of renal
failure. Deaths by embolic events and multiple organ failure syndrome also
significantly decreased during period 2.
Conclusions: A dramatic reduction in mortality was observed during this
study suggesting that a management-based approach has a significant impact
on IE outcome. 
181
Predictors of mitral valve replacement after percutaneous mitral val-
vuloplasty
Leila Abid (1), A Hammami (2), Dorra Abid (3), M Hadrich (1), Salma
Krichène (3), Imen Trabelsi (4), Salma Krichène (1), L Laroussi (1),
Mohamed Sahnoun (5), F Triki (1), S Mallek (1), Mourad Hentati (6),
Samir Kammoun (3)
(1) Hôpital Hédi Chaker, cardiologie, Sfax, Tunisie – (2) Service de Bac-
tériologie de SFAX, Tunisie, Tunisie – (3) CHU hédi CHaker, Sfax, Tuni-
sie – (4) CHU Hédi Chaker, cardiologie, Sfax, Tunisie – (5) CHU hédi
CHaker, cardiologie, Sfax, Tunisie – (6) CHU HEDI CHAKER, Sfax,
Tunisie
Introduction: Percutaneous mitral valvuloplasty (PVM) is an effective
therapy for mitral stenosis in selected patients. Nonetheless, mitral valve
replacement (MVR) may be still required after PVM in some cases. The aim
of this analysis is to assess predictors of MVR after PVM.
Methods: Our retrospective study includes 354 patients enrolled in our
department (1996-2002).
Results: Thirty seven (10, 34%) of 354 patients underwent MVR at a mean
interval of 13,6±9,3 months after PVM. No major differences were apparent
in the demographic features of patients who did or did not undergo surgery.
Five patients (13%) underwent surgery within the first month after PVM while
32 patients (87%) were operated later. On univariate analysis several predic-
tors were brought out: rheumatic antecedents, commissurotomy history, atrial
fibrillation, severe mitral regurgitation before PVM or its aggravation after
PVM, high echocardiography score, calcification, small mitral area, mitral gra-
dient, diastolic and systolic arterial pulmonary pressure before PVM. How-
ever, on multivariate analysis only mitral area, diastolic and systolic arterial
pulmonary pressure could be predictors for surgery.
Conclusion: Certainly, PVM is an excellent treatment option in mitral
stenosis. It is minimally invasive, well-tolerated and has a high success rate.
But the need of surgery after PVM is not uncommon, so if a mitral valve res-
tenosis occurred in patients with predictors of surgery, do we repeat PVM or
directly perform RMV?
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Atrial fibrillation (AF) is a major cause of embolic event, but the signifi-
cance of other arrhythmias remains unknown. The purpose of study was to
assess the significance of unexplained stroke in patients who had apparently
only supraventricular tachycardia (SVT).
Population: Unexplained stroke was noted in 26 patients (pts) (group I)
admitted for palpitations and electrophysiological study (EPS); they were
issued from a population of 1002 pts with normal ECG in sinus rhythm, pal-
pitations or tachycardia and with inducible SVT at EPS; 976 pts had no history
of stroke (group II).
Methods: EPS consisted of atrial pacing and programmed atrial stimula-
tion in control state and if necessary after infusion of isoproterenol. Clinical
and electrophysiological data of both groups were studied. Pts with stroke
had a normal carotid ultrasound study and transcranial Doppler ultrasonog-
raphy.
Results: Pts with unexplained stroke represent 2.5 % of population with
SVT. They were older than remaining pts without stroke (65±10 vs 50±19
years) (p 0.001). They have more frequently associated heart disease (8/26,
31 % vs 37/976, 4 %) (p < 0.001). Male gender was more frequent in group
I (16/26, 60 %) than in group II (355/956, 37 %) (p< 0.05). Typical AV
node re-entrant tachycardia was noted in 17 group I pts (65 %) and 693/976
(68 %) (NS); AV re-entrant tachycardia associated with a concealed acces-
sory pathway was noted in 2 group I pts (8 %) and 168 group I pts (17 %)
(NS); atypical AV node re-entrant tachycardia was more frequent in group
I (7/26, 27 %) than in group II (115/976, 12 %) (p<0.05). AF induction was
more frequent in group I (6/26, 23 %) than in group II (35/976, 3.5 %) (p<
0.001). Ablation was performed in 6 group I pts; one of them died from
another stroke; another one died suddenly; another one developed a perma-
nent AF.
Conclusions: Old age, male gender, associated heart disease, and induction
of atrial fibrillation were significant factors associated with the history of
stroke in pts with SVT. They have a risk of adverse events during the follow-
up. However, unexplained stroke was a rare event in patients with paroxysmal
SVT, noted in 2.5 % of this population.
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Introduction: Brain natriuretic peptide (BNP) is released by the left ven-
tricle (LV) in response to increase LV wall stress and is associated with symp-
toms and outcome in aortic stenosis (AS). However, the relation between
BNP, LV filling pressure and left atrial (LA) volume has been poorly exam-
ined in AS. This study was undertaken to assess the determinants of BNP level
in AS.
Method and results: Two-dimensional, tissue Doppler imaging and
Doppler transthoracic echocardiography were performed in 34 consecutive
patients with severe AS (72±12 years, 62% of male, aortic valve area
(AVA), 0.67±0.2 cm2, mean gradient, 45±13mmHg). Concomitantly, plasma
BNP level was measured. Mean plasma level BNP was 325±572pg/ml. BNP
was significantly higher in patients with reduced LV systolic function (LV
ejection fraction ≤ 60%, n=22; 595±869 vs. 178±235pg/ml, p=0.04),
increased indexed LA volume (≥ 40ml/m2, n=21; 454±686 vs. 125±210pg/
ml, p=0.026) and increased LV filling pressure (E/Ea ratios: septal ≥ 15,
n=17, 562±738 vs. 108±117pg/ml, p=0.004; lateral ≥ 11, n=14, 626±800 vs.
137±139, p=0.02). There were good correlations between BNP and LV and
LA ejection fraction, (r=-0.40, p=0.0035 and r=-0.45, p=0.01), indexed LA
volume (r=0.48, p=0.0049) and with septal and lateral E/Ea ratios (r=0.69,
p<0.0001 and r=0.50, p=0.0054). However, there was lower correlation
between BNP and AVA (r=0.33, p=0.047). After adjustment for age and LV
ejection fraction, multivariate analysis showed that E/Ea septal (p=0.0005)
or lateral (p=0.048) ratios and indexed LA volumes (p=0.006) remained
associated with BNP. Furthermore, symptomatic patients (n=24) had signif-
icantly higher BNP level (427±654 vs.78±112pg/ml, p=0.009) and E/Ea
septal (25±14 vs. 12±7, p=0.01) and lateral ratios (15±7 vs. 10±5, p=0.01)
than asymptomatic patients.
Conclusion: This study shows that BNP release is mainly determined by
both LV and LA function in patients with AS. In this population, BNP level
reflects the ventricular and atrial consequences of increased afterload rather
than the severity of stenosis.
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